At UTHealth Houston, researchers pursuing an unexpected question have found reassurance for thousands of pregnant people at high risk of early delivery: a common sexually transmitted infection does not appear to doom them to repeat that painful experience. The findings, published in The American Journal of Obstetrics and Gynecology, challenge earlier assumptions about Mycoplasma genitalium—a bacterium so tiny and cell-wall-free that it had long evaded both detection and understanding.
Preterm birth, defined as delivery before 37 weeks, remains a leading cause of infant illness and death worldwide. For people who have already experienced one preterm delivery, the prospect of it happening again weighs heavily. So when earlier research hinted that certain Mycoplasma species might contribute to preterm labor, the implication seemed grim: that a persistent infection could trap a person in a cycle of complications. But the science needed testing, because those earlier studies were limited in scope and rigor.
Dr. Irene Stafford, a maternal-fetal medicine physician and first author of the study, led a prospective investigation of nearly 500 pregnant individuals with a history of preterm birth or related complications, enrolled between July 2023 and December 2025. Participants underwent FDA-cleared vaginal swab testing early in pregnancy to detect Mycoplasma genitalium. The results were clear: while 12 percent of participants tested positive for the infection, and the bacterium was significantly more common among those who had experienced prior preterm birth, it did not increase the risk of another spontaneous preterm birth in the current pregnancy. The infection also did not raise the risk of second-trimester loss caused by cervical insufficiency.
The distinction matters profoundly. Mycoplasma genitalium's connection to inflammation had made researchers reasonably cautious—they wondered if it might fuel pregnancy complications. The bacterium is indeed a growing public health concern, linked to HIV acquisition and increasingly resistant to available antibiotics. But this study suggests its threat operates differently than feared. While the infection may be associated with a history of pregnancy complications, it does not appear to drive recurrence in subsequent pregnancies. Stafford and her colleagues propose a possible explanation: Mycoplasma genitalium may pose its greatest risk during a first-time infection, when the body has not yet mounted an immune response.
"For individuals already at high risk of preterm birth, Mycoplasma genitalium infection alone does not seem to increase the likelihood of another early delivery," Stafford said, offering both clarity and compassion for her patients. That distinction—between correlation and causation, between past risk and future risk—can reshape clinical decisions about screening and treatment for some of the most vulnerable pregnancies.
Researchers emphasize that preterm birth is complex, influenced by countless intertwined factors, and that more work lies ahead. Still, these results provide something precious: reassurance grounded in evidence. For people haunted by a previous early delivery, wondering if history must repeat itself, the news offers hope that at least this particular threat may not be inevitable.